Il-19 as a biomarker of tslp treatment
AssigneeMerck Sharp & Dohme Corp.
InventorPia Bjorck
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of IL-19 as a biomarker of treatment with a TSLP antagonist.
Claims18
A method of treating allergic disease in a subject in need thereof comprising measuring expression of IL-19 in a sample from said subject and, if IL-19 levels in the sample are higher than a control, administering a therapeutically effective amount of a TSLP antagonist to the subject.
A method for treating a subject with a TSLP antagonist comprising:
- a) obtaining a first biological sample from the subject prior to administering a dose of a TSLP antagonist;
- b) measuring the expression of IL-19 in the baseline biological sample,
- c) administering the TSLP antagonist to the subject;
- d) obtaining from the subject a second biological sample;
- e) measuring the expression of IL-19 in the second sample;
- f) comparing the expression of IL-19 in the second biological sample with the expression of IL-19 in the first biological sample,
- and, if IL-19 levels are reduced in the second biological sample as compared to the first biological sample, administering a therapeutically effective amount of a TSLP antagonist to the subject.
A method for selecting a subject from treatment with a TSLP antagonist comprising measuring expression of IL-19 in a sample from said subject and, if IL-19 levels in the sample are higher than the levels of a control, then administering a therapeutically effective amount of a TSLP antagonist to the subject.
(canceled)
Dependencies are inferred from the claim text.